RecruitingNot ApplicableNCT07074405

Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer

Understanding the Acceptability of Artificial Intelligence as a Support for Healthcare Providers in the Diagnosis of Prostate Cancer - the Patient at the Heart of His Care


Sponsor

Centre Hospitalier Universitaire de Liege

Enrollment

50 participants

Start Date

Dec 2, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study investigates the acceptability of artificial intelligence (AI) as a diagnostic support tool among patients with localized prostate cancer and healthcare providers, as well as their willingness to share health data for AI development. Background AI tools in healthcare show promising potential, especially in improving diagnosis accuracy and personalizing treatment. However, successful implementation depends not only on technical performance but also on the acceptability of AI among its users-both patients and professionals. Prior research has shown varied acceptability depending on context, disease severity, task performed by AI, and user population. Objectives Assess patients' acceptability of AI as a diagnostic support in prostate cancer. Explore patients' willingness to share health data for developing clinical AI. Assess healthcare providers' acceptability of AI in this diagnostic context. Methodology Design: A cross-sectional, mixed-method, multinational study (Belgium, Italy, Spain). Quantitative Phase: Online questionnaire, using adapted theoretical frameworks (Value Perception Model, NASSS-AI, TFA). Qualitative Phase: Will follow based on quantitative findings. Participants: Adults diagnosed with localized prostate cancer. Recruitment via hospitals, social media, and patient associations. Data Collected: Personal and health information, attitudes toward AI, willingness to share data. Ethics Approved by ethics committees in each participating country. Informed consent obtained digitally before participation. Data anonymized and GDPR-compliant.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how acceptable it is for prostate cancer patients to have artificial intelligence (AI) involved in helping diagnose their condition, to understand patient attitudes and concerns. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with localized prostate cancer (cancer that has not spread beyond the prostate) - You have given consent to participate **You may NOT be eligible if...** - You do not speak French - Your prostate cancer has already spread (metastatic) at the time of diagnosis - You are in a terminal stage of illness - You have an intellectual disability, dementia, or altered state of consciousness Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERQuestionnaire and Physical Exam

This is an online questionnaire that the patients fill in


Locations(1)

CHU Liege

Liège, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07074405


Related Trials